Abstracts tagged "pain"

Abstract Number: 1479 • ACR Convergence 2021
CD14, a Toll-like Receptor Co-Factor, Influences Osteoclast Differentiation and Activity, but Does Not Alter Osteoblastic Potential of Bone-Marrow Precursors in Mice
Jerahme Martinez, Vu Nguyen, Cheng Zhou, George Dodge and Carla Scanzello, University of Pennsylvania, philadelphia, PA
Background/Purpose: Changes in subchondral bone structure (SCB) occur in osteoarthritis (OA), and are visible by imaging as subchondral sclerosis on radiographs, and bone marrow lesions…
Abstract Number: 0405 • ACR Convergence 2020
Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment
Gülen Hatemi¹, Alfred Mahr², Mitsuhiro Takeno³, Doyoung Kim⁴, Melike Melikoğlu¹, Sue Cheng⁵, Sven Richter⁵, Michele Brunori⁶, Maria Paris⁵, Mindy Chen⁵ and Yusuf Yazici⁷, ¹Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, ²Cantonal Hospital St. Gallen, St. Gallen, Switzerland, ³Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, ⁵Amgen Inc., Thousand Oaks, ⁶Amgen Europe GmbH, Rotkreuz, Switzerland, ⁷New York University School of Medicine, New York
Background/Purpose: Recurrent, painful oral ulcers (OU) are common symptoms of Behçet’s syndrome that can impact daily activities and impair quality of life (QoL) (Kokturk A.…
Abstract Number: 0899 • ACR Convergence 2020
Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial
Denis Poddubnyy¹, Effie Pournara², Agnieszka Zielinska³, Asta Baranauskaite⁴, Alejandro Muñoz Jiménez⁵, Sanchayita Sadhu⁶, Barbara Schulz², Michael Rissler², Chiara Perella² and Helena Marzo-Ortega⁷, ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Medycyna Kliniczna, Warszawa, Poland, ⁴Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁵H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ⁶Novartis Healthcare Private Limited, Hyderabad, Telangana, India, ⁷The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
Abstract Number: 1230 • ACR Convergence 2020
Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis
Neha Bhaskar¹, Lilian Otalora Rojas², Tara Jehu¹, Shazia Beg¹ and Neha Bhanusali¹, ¹University of Central Florida College of Medicine, orlando, ²University of Central Florida HCA Healthcare GME, Orlando
Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…
Abstract Number: 1644 • ACR Convergence 2020
Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis
Ali Guermazi¹, Frank Roemer², Andrew Kompel¹, Luis Diaz³, Michel Crema⁴, Mark Brown⁵, Anne Hickman⁵, Glenn Pixton⁶, Lars Viktrup⁷, Robert Fountaine⁵, Aimee Burr⁵, Sarah Sherlock⁵ and Christine West⁸, ¹Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Boston Veteran Affairs Healthcare System, Boston, MA, ⁴Boston University School of Medicine, Paris, France, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc., Morrisville, NC, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
Abstract Number: 1960 • ACR Convergence 2020
Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis
Valia Leifer¹, Jeffrey Katz², Faith Selzer³, Tuhina Neogi⁴, Jamie Collins⁵ and Elena Losina², ¹The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, ²Harvard Medical School / The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA, ³The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Amesbury, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA
Background/Purpose: Growing numbers of knee osteoarthritis (KOA) patients are morbidly obese (BMI ≥ 35 kg/m2). Evolving evidence suggests weight reduction may delay the structural progression…
Abstract Number: 0438 • ACR Convergence 2020
Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Large Private Rheumatology Practice
Jessica Farrell¹, Mitchell Miller¹, Kelsey Hennig², Kelley Powers³, Sooyeon Kwon⁴, Denae Moyer⁵, Kathryn French⁵, Angela Citta⁵ and Jacqueline Cleary¹, ¹Albany College of Pharmacy and Health Sciences, Albany, NY, ²Albany College of Pharmacy and Health Sciences, New Lebanon, NY, ³The Center for Rheumatology, Delanson, NY, ⁴Albany Stratton VA Hospital, Loudonville, NY, ⁵Albany College of Pharmacy and Health Sciences, Albany
Background/Purpose: With the evolution of DMARDs, the need for opioids in the treatment of rheumatic diseases has decreased. However, rheumatology professionals are often presented with…
Abstract Number: 0940 • ACR Convergence 2020
In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
Giovanni Adami¹, Angelo Fassio¹, Elisabetta Gerratana², Alessandro Giollo¹, Camilla Benini¹, Luca Idolazzi¹, Elisabetta Vantaggiato¹, Davide Gatti¹ and Maurizio Rossini¹, ¹Rheumatology Unit, University of Verona, Verona, Italy, ²Rheumatology Unit, University of Messina, Messina, Italy
Background/Purpose: Long-term nociceptive pain, as in inflammatory arthritides, can cause Central Sensitization (CS) to pain. CS Inventory (CSI) is a validated screening instrument for clinicians to…
Abstract Number: 1234 • ACR Convergence 2020
Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab
Ernest Choy¹, Vivian Bykerk², Yvonne Lee³, Gregory St John⁴, Hubert van Hoogstraten⁵, Kerri Ford⁶, Amy Praestgaard⁶ and Anthony Sebba⁷, ¹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ²Hospital for Special Surgery, New York, NY, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Sanofi, Cambridge, MA, ⁷Arthritis Associates, Palm Harbor, Tampa, FL
Background/Purpose: Inflammation is a key driver of pain in rheumatoid arthritis (RA). However, in some patients the level of pain exceeds what would be expected…
Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Luana Colloca¹, Robert Dworkin², John Farrar³, Leslie Tive⁴, Ed Whalen⁵, Jerry Yang⁴, Lars Viktrup⁶, Mark Brown⁷, Christine West⁷ and Kenneth Verburg⁸, ¹University of Maryland, Baltimore, ²University of Rochester School of Medicine and Dentistry, Rochester, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, New York, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Groton
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
Abstract Number: 1968 • ACR Convergence 2020
Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Elena Tchetina¹, Kseniya Glemba¹, Galina Markova¹, Maksim Makarov¹ and Aleksandr Lila¹, ¹Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Osteoarthritis (OA) is a chronic rheumatic disease, which involves pain, limited inflammation, and local destruction of the knee joint. OA pain is a major…
Abstract Number: 0534 • ACR Convergence 2020
National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use
Meghna Jani¹, Belay Yimer¹, Therese Sheppard¹, Mark Lunt¹ and William Dixon¹, ¹Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom
Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…
Abstract Number: 0942 • ACR Convergence 2020
Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study
Mary-Ann Fitzcharles¹, Emmanouil Rampakakis², Yoram Shir¹, John Sampalis², Martin Cohen¹, Michael Starr¹ and Winfried Häuser³, ¹McGill University, montreal, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Technische Universität München, Munich, Germany
Background/Purpose: Treatment strategies for chronic widespread pain (CWP)/fibromyalgia (FM) are imperfect with only a modest effect from medications. Due to the many symptoms experienced by…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1646 • ACR Convergence 2020
Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events
Jayeshkumar Patel¹, Wenhui Wei², Raveendhara Bannuru³, Ravi Iyer⁴, Nazneen Fatima Shaikh¹, Traci LeMasters¹, Chibuzo Iloabuchi¹, Degang Wang² and Usha Sambamoorthi¹, ¹West Virginia University School of Pharmacy, Morgantown, WV, ²Regeneron Pharmaceuticals, Tarrytown, NY, ³Tufts Medical Center, Boston, MA, ⁴Teva Pharmaceutical Industries, West Chester, PA
Background/Purpose: NSAIDs are commonly used for OA pain, but the benefits of pain relief must be carefully weighed against the potential risk for gastrointestinal (GI),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].